Cadrenal Launches Strategic Review, Hires Tungsten Advisors
PONTE VEDRA, Fla. – – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) has opened a formal strategic process covering its entire four-asset pipeline, with options ranging from asset sales to a full business combination. The Board of Directors initiated the review to maximize value for shareholders, and Tungsten Advisors will act as exclusive strategic financial advisor.
Four programs, from Phase 3-ready to preclinical, are in scope
The review covers CAD-1005, tecarfarin, frunexian and CAD-2000, the company's second-generation 12-LOX platform. Cadrenal says the process builds on ongoing partnering discussions.
Potential transactions include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions and business combinations.